BioNexus Gene Lab Corp
BGLC Nasdaq· Services-Medical Laboratories
Last close · Oct 27, 2026
$1.13
KIRA · Stoqly’s AI analyst, in plain words
- BioNexus Gene Lab Corp had $7.4M of revenue in fiscal 2025, down 21.9% on the year before. Over five years, revenue changed −8.2% a year on average.
- Its operating margin was −39.9%, down 23.4 pts: of every 100 in sales, about −40 is left after running the business.
- BioNexus Gene Lab Corp lost $3.0M in fiscal 2025.
- Free cash flow was −$1.9M in fiscal 2025, −25.3% of revenue.
Market cap
$2.7M
P/E
—
Revenue
$7.4M
Net income
−$3.0M
Free cash flow
−$1.9M
Operating margin
−39.9%
BioNexus Gene Lab Corp in 30 seconds · fiscal 2025
Are sales growing?
−21.9%
No. Sales fell 21.9% last year.
Does it make a profit?
−40.2%
No. It lost money last year.
Does profit turn into cash?
−25.3%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
What BioNexus Gene Lab Corp does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Apr 14, 2026
- Legal name
- BioNexus Gene Lab Corp
- CIK
- 0001737523
BioNexus Gene Lab Corp · BGLC
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $13.4M | $10.9M | $9.8M | $9.5M | $7.4M |
| Revenue growth | 17.3% | −18.2% | −10.6% | −2.7% | −21.9% |
| Net interest income | — | $0.0M | $0.0M | — | — |
| Gross margin | 17.0% | 11.5% | 13.6% | 13.6% | 14.6% |
| Operating margin | 7.9% | −2.7% | −26.5% | −16.5% | −39.9% |
| Net income | $0.8M | −$0.4M | −$2.6M | −$1.6M | −$3.0M |
| Net margin | 5.6% | −3.3% | −26.9% | −16.8% | −40.2% |
| Diluted EPS | — | — | −$0.17 | −$0.09 | — |
| Cash | |||||
| Cash from operations | $0.0M | $0.6M | −$1.8M | −$2.1M | −$1.8M |
| Capital expenditure | $0.0M | $0.0M | $0.1M | $0.2M | $0.0M |
| Free cash flow | $0.0M | $0.6M | −$2.0M | −$2.3M | −$1.9M |
| FCF margin | 0.0% | 5.0% | −20.2% | −24.4% | −25.3% |
| Share count change | — | — | — | 12.2% | — |
| Debt and strength | |||||
| Cash and short-term investments | $2.1M | $2.1M | $4.5M | $2.9M | $2.4M |
| Shareholders' equity | $7.2M | $6.7M | $9.7M | $8.3M | $8.6M |
| Current ratio | 3.1x | 3.0x | 4.9x | 3.8x | 10.5x |
| Interest coverage | — | −23.3x | −186.6x | — | — |
| Returns and quality | |||||
| Return on equity | 10.9% | −5.1% | −32.2% | −17.8% | −35.2% |
| Return on tangible equity | 10.5% | −5.3% | −27.2% | −19.2% | −34.6% |
| Piotroski F-score | 5 | 2 | 3 | 2 | 3 |
| Altman Z'' | 7.7 | 6.6 | 7.5 | 5.5 | 13.3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
BioNexus Gene Lab Corp · BGLC
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.13 a share, the company is worth $2.7M.
Source: SEC EDGAR XBRL filings (CIK 0001737523). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.